GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia

• Published in: The lancet oncology 2024-06, Vol.25 (6), p.685-687
• Main Author: Rogers, Kerry A
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use; Chronic lymphocytic leukemia; Clinical trials; Comorbidity; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Rituximab; Standard of care; Sulfonamides - therapeutic use; Survival
• ISSN: 1470-2045; 1474-5488; 1474-5488
• DOI: 10.1016/S1470-2045(24)00260-2

The GAIA/CLL13 study is a phase 3 trial that answers several important questions about how to treat patients with chronic lymphocytic leukaemia.1,2 In The Lancet Oncology, Moritz Fürstenau and colleagues now report updated 4-year follow up data in an exploratory analysis.1 In the study, treatment-naive, fit patients with chronic lymphocytic leukaemia were randomly assigned to one of four treatment groups. The initial report of this study showed improved progression-free survival with venetoclax–obinutuzumab and venetoclax–obinutuzumab–ibrutinib compared with chemoimmunotherapy and established venetoclax–obinutuzumab as a preferred regimen for fit patients, since previous studies had been in patients with comorbidities.2,3 With additional follow-up (median of 50·7 months [IQR 44·6–57·9]), progression-free survival was still significantly improved for venetoclax–obinutuzumab (hazard ratio [HR] 0·47 [97·5% CI 0·32–0·69], p